Lipid Nanoparticle (LNP) Production by High Pressure Homogenizer ? Complete Guide

# Lipid Nanoparticle (LNP) Production by High Pressure Homogenizer

Lipid nanoparticles (LNPs) are the most clinically advanced non-viral delivery system for nucleic acid therapeutics, including mRNA vaccines ?, including mRNA vaccines (COVID-19), siRNA drugs (Onpattro), and gene-editing therapies (CRISPR-Cas9). High pressure homogenization has emerged as a scalable, GMP-compliant method for LNP production ? capable of producing particles with controlled size (50?150 nm), narrow polydispersity, and high encapsulation efficiency.

> LNPs are the most clinically successful non-viral delivery system for mRNA therapeutics ? but manufacturing them at scale with tight particle size control is still a challenge. If you’re developing an LNP formulation or scaling up production, here’s how HPH fits into the process and what parameters matter.

This guide covers LNP manufacturing using HPH, from lab-scale formulation to commercial production.

What Are Lipid Nanoparticles?

Lipid nanoparticles are spherical vesicles composed of:

LNPs are distinct from liposomes ? LNPs have a more amorphous internal structure compared to the bilayer vesicle structure of liposomes.

Why High Pressure Homogenization for LNPs?

HPH offers the best combination of scalability, GMP compliance, and particle size control ? particularly important as LNP therapies move from clinical trials to commercial manufacturing.

The LNP Manufacturing Process with HPH

Step 1: Lipid Dissolution

Lipids are dissolved in ethanol at controlled ratios. The lipid composition is typically:

Step 2: Aqueous Phase Preparation

An aqueous buffer (typically 20?50 mM citrate, acetate, or phosphate buffer, pH 4.0?5.5) is prepared containing the nucleic acid cargo.

Step 3: Ethanol Injection

The ethanol lipid phase is rapidly injected into the aqueous phase under controlled flow conditions. This creates a crude LNP suspension with particles typically > 200 nm.

Step 4: High Pressure Homogenization

The crude LNP suspension is processed through a high pressure homogenizer to achieve the target particle size:

Step 5: Ethanol Removal & Buffer Exchange

Diafiltration or tangential flow filtration (TFF) removes ethanol and exchanges the buffer to the final formulation buffer (e.g., PBS, pH 7.4, or Tris-sucrose).

Step 6: Sterile Filtration

0.2 ?m filtration for sterilization. Final LNP formulations are typically 0.5?5 mg/mL RNA concentration.

HPH Process Optimization for LNPs

Effect of Pressure on LNP Size

Higher pressure produces smaller, more uniform particles ? but can also reduce encapsulation efficiency if excessive shear degrades the nucleic acid.

Effect of Passes

3?5 passes at 800?1000 bar is the optimal balance for most LNP formulations.

Temperature Control

Temperature control is critical during HPH of LNPs:

LNP Homogenizer vs Microfluidics

For LNP production at commercial scale (10?500 kg/year), HPH is generally more cost-effective than microfluidics.

Choosing the Right Equipment for LNP Production

Quality Control for LNP Products

Regulatory Requirements to Know

HPH-based LNP manufacturing follows ICH Q8 (Pharmaceutical Development), Q9 (Risk Management), and Q10 (Pharmaceutical Quality System) guidelines. Key GMP considerations:

Quick Answers to Common Questions

Q: Can I use a high pressure homogenizer for mRNA-LNP production?

Yes. High pressure homogenization is a well-established method for LNP production. The process involves ethanol injection to form crude LNPs, followed by HPH to achieve the target particle size of 50?150 nm with low polydispersity.

Q: What pressure is needed for LNP homogenization?

Optimal pressure is typically 800?1000 bar for LNP production. Higher pressures (up to 1500 bar) can produce smaller particles but may reduce encapsulation efficiency with longer processing.

Q: How does HPH compare to microfluidics for LNP manufacturing?

HPH offers better scalability and lower operating costs for commercial production. Microfluidics provides more uniform shear but is limited by channel scaling and has higher consumable costs. Many manufacturers use both: microfluidics for early development, HPH for commercial scale-up.

Q: Can I use the same homogenizer for liposomes and LNPs?

Yes. Many liposome manufacturing processes use the same HPH equipment as LNP production ? but different process parameters and cleaning procedures apply.

Q: What lipid composition is used for LNP?

Standard LNP formulations contain ionizable lipid (40?50 mol%), helper phospholipid like DSPC (10 mol%), cholesterol (38?40 mol%), and PEG-lipid (1.5?3 mol%). The specific ionizable lipid depends on the therapeutic application.

Q: Is HPH scalable for commercial LNP production?

Yes. HPH is linearly scalable from 10 mL/h lab units to 5000 L/h industrial systems, making it ideal for the growing LNP therapeutics market.

Q: What is the encapsulation efficiency of HPH-processed LNPs?

With optimized process parameters, HPH-processed LNPs typically achieve 85?95% encapsulation efficiency for siRNA and 70?90% for mRNA.

Q: Does high pressure homogenization damage mRNA?

At optimized conditions (800?1000 bar, 3?5 passes, temperature control at 4?15?C), HPH processing preserves > 70% mRNA integrity ? comparable to microfluidic methods.

> ? Developing LNPs? Start with our PTH-10 ? same parameters scale directly to production. **? View PTH-10 LNP Setup ?

Where to Go Next ? Based on Your Stage

References

? Lipid nanoparticles for mRNA delivery: manufacturing and characterization, Nature Reviews Drug Discovery, 2023. View on PubMed ?

Internal Links